FDA 483 - Pioneer Surgical Technology Inc. - June 14, 2024

Pioneer Surgical Technology Inc., a medical device manufacturer, was inspected by the FDA from June 10-14, 2024, at its Marquette, MI facility. The inspection resulted in observations highlighting significant deficiencies in the company's quality management system, indicating a need to adhere to regulatory expectations for medical device production.

The primary observation centered on the inadequate establishment of procedures for corrective and preventive actions (CAPA). This included issues such as failing to properly identify CAPA risk, exemplified by a 'medium risk' classification for medical devices potentially exposed to chemicals without adequate supporting evaluations. The company also demonstrated a lack of timely resolution for high-risk CAPAs and failed to comprehensively address identified root causes across all affected areas. Further shortcomings were noted in the absence of clear acceptance criteria for verifying CAPA effectiveness and a process for managing overdue corrective actions.

A secondary observation pointed to insufficient procedures for training and identifying training needs. A specific instance revealed a Quality Inspector lacked a required training record for a critical procedure, indicating a gap in ensuring personnel are adequately trained.

To address these findings, Pioneer Surgical Technology Inc. must develop and implement comprehensive corrective actions for each observation. This involves revising CAPA procedures to ensure thorough risk assessment, timely completion, robust root cause analysis, clear effectiveness verification, and a system for managing overdue tasks, alongside strengthening training documentation and compliance to align its quality system with regulatory standards for medical devices.